Shanghai C&D Innostic Medical Technology 建发致新
9 significant filings since 1 Jun 2026: 4 on guarantee or financial assistance, 2 on new listing and 1 on dividend, and 2 other kinds. The latest, on 22 Sep 2026: 关于部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通提示性公告. On 15 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 2.16% to 16.76% from the same period a year earlier.
自 1 Jun 2026 起有 9 份重大公告：guarantee or financial assistance 4 份、new listing 2 份、dividend 1 份，另有 2 类。最新一份（22 Sep 2026）：关于部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通提示性公告。15 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 2.16% 至 16.76%。
Price History 价格走势
243 trading days 个交易日 · High 最高 ¥38.76 · Low 最低 ¥18.28| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥77亿 | ¥58亿 | 11th highest of 30 · 30 家中第 11 高 | |
| Trailing P/E 市盈率 | 27.6x | 23.1x | 9th highest of 25 · 25 家中第 9 高 | |
| P/B 市净率 | 3.5x | 1.2x | 4th highest of 30 · 30 家中第 4 高 | |
| Revenue Growth 营收增速 | 1.8% | 0.3% | 13th highest of 30 · 30 家中第 13 高 | |
| Profit Growth 净利增速 | 8.0% | -7.2% | 11th highest of 30 · 30 家中第 11 高 | |
| Gross Margin 毛利率 | 8.1% | 11.2% | 8th lowest of 30 · 30 家中第 8 低 | |
| Net Margin 净利率 | 1.9% | 1.6% | 13th highest of 30 · 30 家中第 13 高 | |
| Return on Equity 净资产收益率 | 6.8% | 3.0% | 4th highest of 30 · 30 家中第 4 高 | |
| Debt to Assets 资产负债率 | 84.6% | 61.0% | 2nd highest of 30 · 30 家中第 2 高 | |
| Grade Score 评级得分 | 48 | 47 | 14th highest of 30 · 30 家中第 14 高 |
Statement figures are for the period to 30 Jun 2026, filed by 30 of 30 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，30 家同业中 30 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shanghai Pharma 上海医药 | ¥589亿 | 12.3x | 0.8x | 4.2% | 2.9% | 4.5% | C |
| Yifeng Pharmacy 益丰药房 | ¥272亿 | 15.5x | 2.3x | 3.5% | 8.8% | 8.0% | B |
| Jointown 九州通 | ¥249亿 | 12.4x | 0.9x | 7.6% | 1.4% | 4.2% | D |
| DaShenLin Pharmaceutical Group 大参林 | ¥202亿 | 14.8x | 2.7x | 3.5% | 7.2% | 11.6% | B |
| China National Medicines 国药股份 | ¥195亿 | 10.1x | 1.0x | 4.3% | 3.3% | 4.7% | C |
| China Meheco 中国医药 | ¥132亿 | 30.9x | 1.1x | -0.7% | 1.8% | 2.1% | D |
| Qingdao Baheal Medical 百洋医药 | ¥131亿 | 24.5x | 5.7x | -5.1% | 7.9% | 9.3% | C |
| China National Accord Medicines 国药一致 | ¥119亿 | 11.1x | 0.6x | -1.4% | 1.8% | 3.2% | D |
| Lbx Pharmacy Chain 老百姓 | ¥99亿 | 22.9x | 1.4x | 2.1% | 4.8% | 6.6% | C |
| C.Q. Pharmaceutical Holding 重药控股 | ¥89亿 | 24.9x | 0.8x | -2.6% | 0.8% | 2.2% | E |
| Shanghai C&D Innostic Medical Technology 建发致新 | ¥77亿 | 27.6x | 3.5x | 1.8% | 1.9% | 6.8% | D |
| Nanjing Pharmaceutical Group 南京医药 | ¥64亿 | 10.3x | 0.9x | -0.5% | 1.4% | 4.0% | D |
| Yixintang Pharmaceutical Group 一心堂 | ¥63亿 | 23.1x | 0.8x | -5.0% | 3.1% | 3.5% | C |
| Guangxi Liuyao Group 柳药集团 | ¥60亿 | 9.2x | 0.8x | 2.2% | 3.5% | 4.6% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。